Orforglipron vs Semaglutide
Both are now approved: one a weekly injection with a cardiovascular outcomes trial behind it, the other a once-daily pill whose case rests on access, not peak efficacy.
Orforglipron
~11% in ATTAIN-1; a scalable oral pill whose appeal is access, not peak efficacy. FDA-approved for weight management (Foundayo, 2026) — the type-2 diabetes indication is still under review.
Full Orforglipron evidence reviewSemaglutide
Wegovy / Ozempic
~15% mean weight loss in STEP 1; the benchmark that opened modern obesity medicine.
Full Semaglutide evidence reviewSide by side
| Orforglipron | Semaglutide | |
|---|---|---|
| Marketed for | Weight loss, type-2 diabetes | Weight loss, type-2 diabetes |
| Evidence grade | FDA-approved | FDA-approved |
| Family | GLP-1 / incretin | GLP-1 / incretin |
| Regulatory status | FDA-approved | FDA-approved |
| How it's obtained | Rx product | Rx product |
| Key human source | ATTAIN-1, NEJM 2025 | STEP 1, NEJM 2021 |
marks a row where the two differ. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
Our verdict
Both can be prescribed — orforglipron was FDA-approved for weight management in 2026 as Foundayo — but semaglutide has by far the deeper evidence base, with STEP 1 plus the SELECT cardiovascular result. On weight, semaglutide reported about 14.9% in STEP 1 against roughly 11% for orforglipron in ATTAIN-1, though those come from separate trials and were not compared directly. Orforglipron's real argument is form: a non-peptide small molecule taken as a once-daily tablet with no food or water restrictions. It has no long-term cardiovascular or renal outcomes data yet, and its type-2 diabetes indication is still under review.
Orforglipron fits if
You want a GLP-1 you can swallow rather than inject, with no food or water timing rules, and you accept a shallower outcomes record for that convenience.
Semaglutide fits if
You want a GLP-1 available now, with pivotal weight-loss trials and a dedicated cardiovascular outcomes trial behind it.